Combining liver-directed therapy and a new immunotherapy for liver cancer
Part of Cancer, Digestive system clinical trials.
This study tests a new combination treatment for liver cancer that cannot be removed by surgery. It combines a procedure called TACE (which delivers chemotherapy directly to the tumor) with an investigational drug, ivonescimab, which helps the immune system fight cancer. The goal is to see if this combination is safe and effective for people whose cancer has not spread beyond the liver.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be at least 18 years old.
- You have a confirmed diagnosis of hepatocellular carcinoma (the most common type of liver cancer), and your cancer is not suitable for surgery or other curative treatments.
- Your cancer is limited to the liver and has not spread to other organs.
- Your liver function is moderately good, with a score of 5 to 7 on the Child-Pugh scale.
- You are able to perform daily activities with minimal help (ECOG score between 0 and 1).
- You have not had certain prior treatments for this cancer, including TACE, other liver-directed procedures, or systemic cancer therapies.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study combines a liver-directed procedure called TACE (which blocks blood flow to the tumor and delivers chemotherapy directly to it) with two immunotherapy drugs and a targeted therapy (bevacizumab). The goal is to see if this combination can shrink liver cancer that cannot be surgically removed, without the cancer having spread elsewhere.
This trial tests a new immunotherapy drug (GKL-006) combined with a standard treatment called TACE (which blocks blood flow to the tumor) for people with liver cancer that cannot be removed by surgery. The goal is to see if adding this drug helps shrink tumors more than TACE alone.
This trial tests a new combination of two immunotherapy drugs plus a targeted therapy and a procedure called TACE (which blocks the blood supply to the tumor) for people with advanced liver cancer. It aims to see if this combination can shrink tumors and help patients live longer.
This trial is for people with advanced liver cancer (HCC) that has spread outside the liver. It tests whether combining a TACE procedure with immunotherapy and anti-angiogenesis drugs can improve outcomes. You must not have had prior systemic therapy and must have received TACE in a specific time window around starting these drugs.
This trial tests if giving a combination of drugs (apatinib and camrelizumab) along with a procedure called TACE before surgery can help treat a certain type of liver cancer. The goal is to shrink the tumor before the operation to improve outcomes.
This trial tests a combination of an immunotherapy drug (QL1706) and a liver-directed procedure (TACE) before and after surgery for people with liver cancer that is larger or more advanced than the usual transplant criteria. The goal is to see if this approach can help shrink the tumor and improve outcomes.
Hear when a new Hepatocellular Carcinoma (HCC) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.